Priapism, abnormally prolonged penile erection in the absence of sexual excitation, is associated with ischemia-mediated erectile tissue damage and subsequent erectile dysfunction. It is common among males with sickle cell disease (SCD), and SCD transgenic mice are an accepted model of the disorder. Current strategies to manage priapism suffer from a poor fundamental understanding of the molecular mechanisms underlying the disorder. Here we report that mice lacking adenosine deaminase (ADA), an enzyme necessary for the breakdown of adenosine, displayed unexpected priapic activity. ADA enzyme therapy successfully corrected the priapic activity both in vivo and in vitro, suggesting that it was dependent on elevated adenosine levels. Further genetic and pharmacologic evidence demonstrated that A2B adenosine receptor-mediated (A2BR-mediated) cAMP and cGMP induction was required for elevated adenosine-induced prolonged penile erection. Finally, priapic activity in SCD transgenic mice was also caused by elevated adenosine levels and A2BR activation. Thus, we have shown that excessive adenosine accumulation in the penis contributes to priapism through increased A2BR signaling in both Ada -/- and SCD transgenic mice. These findings provide insight regarding the molecular basis of priapism and suggest that strategies to either reduce adenosine or block A2BR activation may prove beneficial in the treatment of this disorder.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267015PMC
http://dx.doi.org/10.1172/JCI33467DOI Listing

Publication Analysis

Top Keywords

scd transgenic
12
transgenic mice
12
priapic activity
12
contributes priapism
8
adenosine
8
a2b adenosine
8
prolonged penile
8
penile erection
8
ada enzyme
8
elevated adenosine
8

Similar Publications

The transsulfuration (TSS) pathway is an alternative source of cysteine for glutathione synthesis. Little of the TSS pathway in antioxidant capacity in sickle cell disease (SCD) is known. Here, we evaluate the effects of TSS pathway activation through cystathionine beta-synthase (CBS) to attenuate reactive oxygen species (ROS) and ferroptosis stresses in SCD.

View Article and Find Full Text PDF

We describe a patient with sickle cell disease (SCD) and elevated antiphospholipid antibodies (aPL) who developed multi-organ failure resembling catastrophic antiphospholipid syndrome. Autoimmune screening revealed several autoantibodies characteristic of systemic lupus erythematosus (SLE). Notably, routinely housed and unmanipulated transgenic sickle mice displayed significantly elevated titres of aPL- and SLE-associated autoantibodies.

View Article and Find Full Text PDF

Vector-Free Deep Tissue Targeting of DNA/RNA Therapeutics via Single Capacitive Discharge Conductivity-Clamped Gene Electrotransfer.

Adv Sci (Weinh)

November 2024

Translational Neuroscience Facility, Department of Physiology, School of Biomedical Sciences, Graduate School of Biomedical Engineering, Tyree Institute for Health Engineering (IHealthE), UNSW, Sydney, NSW, 2052, Australia.

Viral vector and lipid nanoparticle based gene delivery have limitations around spatiotemporal control, transgene packaging size, and vector immune reactivity, compromising translation of nucleic acid (NA) therapeutics. In the emerging field of DNA and particularly RNA-based gene therapies, vector-free delivery platforms are identified as a key unmet need. Here, this work addresses these challenges through gene electrotransfer (GET) of "naked" polyanionic DNA/mRNA using a single needle form-factor which supports "electro-lens" based compression of the local electric field, and local control of tissue conductivity, enabling single capacitive discharge minimal charge gene delivery.

View Article and Find Full Text PDF

Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation.

Clin Sci (Lond)

December 2024

Section of Cardiorenal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, U.S.A.

Article Synopsis
  • * In research using mice, SCD was found to enhance vasoconstriction (narrowing of blood vessels) through the alpha-1 adrenergic receptor, particularly by increasing the expression of the alpha-1a receptor in the aortic tissue of SCD mice compared to controls.
  • * Treatment with ambrisentan, an ETA receptor blocker, improved blood vessel function in both mice and SCD patients, suggesting that targeting the ET-1 pathway could help improve vascular health in individuals with
View Article and Find Full Text PDF
Article Synopsis
  • - Sickle cell disease (SCD) is caused by mutations in the hemoglobin beta chain gene, leading to the production of abnormal hemoglobin (HbS), which results in symptoms like anemia and painful vaso-occlusive events.
  • - Gene therapy shows promise for treating SCD, with two specific therapies already on the market, but there is a need to enhance their effectiveness, particularly with strategies that involve transferring a corrective beta-globin gene.
  • - Research demonstrates that using cyclosporin H (CsH) during the gene therapy process can improve transgene expression and the number of gene copies in stem cells from cord blood, making it a potential effective combination for treating SCD.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!